Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

被引：0

作者：

Wallace, Daniel J. ^{[1
]}

Furie, Richard ^{[2
]}

Tanaka, Yoshiya ^{[3
]}

Kalunian, Kenneth C. ^{[4
]}

Mosca, Marta ^{[5
]}

Petri, Michelle ^{[6
]}

Dorner, Thomas ^{[7
,8
]}

Cardiel, Mario H. ^{[9
]}

Bruce, Ian N. ^{[10
]}

Gomez, Elisa ^{[11
]}

DeLozier, Amy M. ^{[11
]}

Janes, Jonathan ^{[11
]}

Linnik, Matthew D. ^{[11
]}

de Bono, Stephanie ^{[11
]}

Silk, Maria E. ^{[11
]}

Hoffman, Robert W. ^{[11
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA

[2] Zucker Sch Med Hofstra Northwell, Div Rheumatol, Great Neck, NY USA

[3] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan

[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

[5] Univ Pisa, Pisa, Italy

[6] Johns Hopkins Univ, Sch Med, Med Rheumatol, Baltimore, MD USA

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Deutsch Rheumaforschungszentrum DRFZ, Berlin, Germany

[9] Ctr Invest Clin Morelia SC, Morelia, Michoacan, Mexico

[10] Univ Manchester, Div Musculoskeletal & Dermatol Sci, Ctr Musculoskeletal Res, Manchester, Lancs, England

[11] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

970

引用

页数：2

共 50 条

[41] Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous, Dose-Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus
Szepietowski, Jacek C.
Nilganuwong, Surasak
Wozniacka, Anna
Kuhn, Annegret
Nyberg, Filippa
van Vollenhoven, Ronald F.
Bengtsson, Anders A.
Reich, Adam
de Vries, Dick E.
van Hartingsveldt, Bart
Robinson, Donald W., Jr.
Gordon, Robert
Hsu, Benjamin
ARTHRITIS AND RHEUMATISM, 2013, 65 (10): : 2661 - 2671
[42] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple, Intravenous, Ascending-Dose Study of Sirukumab in Patients with Cutaneous or Systemic Lupus Erythematosus.
Szepietowski, Jacek C.
Nilganuwong, Surasak
Wozniacka, Anna
Kuhn, Annegret
Nyberg, Filippa
Szechinski, Jacek
van Vollenhoven, Ronald F.
Bengtsson, Anders
Reich, Adam
de Vries, Dick
van Hartingsveldt, Bart
Zhou, Bei
Hsu, Benjamin
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S496 - S497
[43] BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
van Vollenhoven, Ronald
Furie, Richard
Kalunian, Kenneth
Dall'Era, Maria
Werth, Victoria
Huang, Xiaobi
Carroll, Hua
Musselli, Cristina
Barbey, Catherine
Franchimont, Nathalie
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3643 - 3644
[44] A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING DOSE STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF CC 220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Furie, R.
Werth, V. P.
Lee, E.
Box, E.
Fondal, M.
Kivitz, A.
Chatham, W. W.
Kalunian, K. C.
Legerton, C.
Anolik, J. H.
Korish, S.
Hough, D. R.
Weiswasser, M.
Choi, S.
Schafer, P.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S77 - S77
[45] Changes in Gut Microbiota and Systemic Inflammation after Synbiotic Supplementation in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Trial
Widhani, Alvina
Djauzi, Samsuridjal
Suyatna, Franciscus Dhyanagiri
Dewi, Beti Ernawati
CELLS, 2022, 11 (21)
[46] Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Pike, Marilyn
Merrill, Joan
Morand, Eric
van Vollenhoven, Ronald
Werth, Victoria
Hobar, Coburn
Delev, Nikolay
Shah, Vaishali
Sharkey, Brian
Wegman, Thomas
Catlett, Ian M.
Banerjee, Subhashis
Singhal, Shalabh
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2219 - 2221
[47] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Morand, E.
Pike, M.
Merrill, J. T.
Van Vollenhoven, R.
Werth, V. P.
Hobar, C.
Delev, N.
Shah, V.
Sharkey, B.
Wegman, T.
Catlett, I.
Banerjee, S.
Singhal, S.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 209 - 209
[48] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Wallace, Daniel J.
Kalunian, Kenneth
Petri, Michelle A.
Strand, Vibeke
Houssiau, Frederic A.
Pike, Marilyn
Kilgallen, Brian
Bongardt, Sabine
Barry, Anna
Kelley, Lexy
Gordon, Caroline
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 183 - 190
[49] Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus
Aranow, Cynthia
Kamen, Diane L.
Dall'Era, Maria
Massarotti, Elena M.
Mackay, Meggan C.
Koumpouras, Fotios
Coca, Andreea
Chatham, W. Winn
Clowse, Megan E. B.
Criscione-Schreiber, Lisa G.
Callahan, Sherri
Goldmuntz, Ellen A.
Keyes-Elstein, Lynette
Oswald, Michaela
Gregersen, Peter K.
Diamond, Betty
ARTHRITIS & RHEUMATOLOGY, 2015, 67 (07) : 1848 - 1857
[50] Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
Stohl, William
Schwarting, Andreas
Okada, Masato
Scheinberg, Morton
Doria, Andrea
Hammer, Anne E.
Kleoudis, Christi
Groark, James
Bass, Damon
Fox, Norma Lynn
Roth, David
Gordon, David
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (05) : 1016 - 1027

← 1 2 3 4 5 →